Boston Scientific Corporation · NYSE:BSX
Boston Scientific — Transcatheter Cardiovascular Therapeutics (TCT) 2017
9 slides from Boston Scientific's conference presentation, Oct 30, 2017
Slide 1: Transcatheter Cardiovascular Therapeutics Investor Update
Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice President and Global Chief Medical Officer Nicholas Spadea-Anello Structural Heart-LAAC Vice Presid
Slide 2: Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers
Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words li
Slide 3: Broadest Portfolio to Drive IC Category Leadership
Broadest Portfolio to Drive IC Category Leadership Coronary Therapies Structural Heart Complex PCI Stents TAVR LAAC Mitral PCI Guidance Coronary Therapies Structural Heart Total Cardiology 2016 Market Size $7.5B $3B $10.5B 5yr CAGR (2016-2021) 1% +17% +7% Est. 2021 Market Size $8.0B $6.5B $14.5B Est
Slide 4: Diversifying into Faster Growth IC Markets
Diversifying into Faster Growth IC Markets Maintain coronary therapies leadership + grow structural heart platforms = healthy IC portfolio diversification BSX IC Revenue Mix 2016 2021E 10% ~40% ~30% 54% 36% Structural Heart ~30% Complex PCI Stents Market Size = $10.5B Market Size = $14.5B 4 4
Slide 5: Compelling TAVR Portfolio: Expand Your Reach
Compelling TAVR Portfolio Expand Your Reach More Options for Better Outcomes ACURATE neo™ Aortic Valve System – EU • Commercial expansion with ACURATE neo TF and TA • Launch next generation ACURATE neo AS H2:18E LOTUS Edge™ Aortic Valve System • EU launch Q1:18E and U.S. launch mid-2018E Accessory D
Slide 6: WATCHMAN LAAC Device Global Leadership
WATCHMAN™ LAAC Device Global Leadership WATCHMAN™ Commercial Activities • Therapy development efforts continue • Focus on penetrating U.S. indicated population • 1% of penetration = $250M • TV campaign showing strong patient activation • Pilot market growth is above national average • Main CMS DRG f
Slide 7: Unrivaled DES Innovation
Unrivaled DES Innovation • YTD 2017: DES growth at market rates despite double digit 2016 growth comparison #1 • Comprehensive clinical science: • SYNERGY™ studied in ~20,000 patients US DES • Unique and differentiated tiered portfolio Market Share • Future product innovation: • 48 mm SYNERGY™ • 4.5
Slide 8: Unmatched Complex PCI and Imaging Portfolios
Unmatched Complex PCI and Imaging Portfolios Clear Leadership in $2.5B Continued Investment in Complex PCI Market Imaging Portfolio New Devices for cPCI Robust and consistent product cadence continues in 2018 8
Slide 9: IC Category Leadership via Breadth of Portfolio
IC Category Leadership via Breadth of Portfolio 9
Boston Scientific — Transcatheter Cardiovascular Therapeutics (TCT) 2017 on 6ix